Why Is TELADOC HEALTH INC (TDOC) Stock Moving Today?

TDOC stock is moving sharply lower today, down nearly 20% in premarket trading, driven by the company’s disappointing Q2 earnings results and a weaker-than-expected revenue forecast. The stock opened with a significant gap down from the prior close of $9.18 to $7.39, signaling immediate investor concern over the company’s performance and outlook. The Integrated Care segment showed stronger profitability, but weaker-than-expected cash-pay revenue at BetterHelp and a revised 2026 revenue forecast of $2.36B, $2.45B have raised concerns about the company’s long-term growth trajectory.

What Happened

Teladoc Health reported second-quarter results that fell short of expectations, with revenue declining 1.5% year over year and a negative earnings per share of $0.96 for the trailing twelve months. The company attributed the weaker performance to a shift in demand at BetterHelp, where cash-pay revenue has declined. In response, Teladoc cut its 2026 revenue guidance, which has triggered a sharp sell-off in its shares. The stock continued to decline throughout the morning session, hitting a low of $6.43 before stabilizing slightly at $6.56 in late morning trading.

What The Data Shows

The stock’s intraday session has been marked by heavy volume, with 24.9 million shares traded, 5.4 times the 3-month average. The stock’s price trend has been negative over the past eight sessions, falling from $9.65 to $9.18. Teladoc’s fundamentals remain weak, with a market cap of $1.7B, a net margin of -6.8%, and a beta of 2.10, indicating high volatility. Additionally, insiders have sold $627K worth of shares over the past 90 days, with the most recent filing on July 6. Unusual options activity has also been noted, with $24K in call premium traded and no put activity, the largest single print being $22K.

What To Watch

Teladoc has not announced an upcoming earnings date, but investors will closely monitor coverage breadth and any further revisions to its 2026 guidance. Analysts from Canaccord Genuity and Evercore ISI Group have both lowered their price targets, and the stock’s performance will likely depend on whether the company can address its cash-pay challenges and stabilize its revenue outlook.